Replacing Legacy Viral Safety Testing Methods with NGS

[Article Title]

Biologics are life-changing but vulnerable products. They are inherently vulnerable to viral contamination due to their reliance on animal- or human-derived starting materials and complex manufacturing processes. Viral contamination incidents, while rare, can threaten patient safety, disrupt production, and damage reputations. Traditional virus detection methods have served the industry for decades, but increasing product complexity and faster drug product supply demand more efficient and advanced technologies for viral contaminant detection. Next-generation sequencing (NGS) enables fast, agnostic, broad, and highly sensitive virus detection and identification.

In this white paper from Charles River Laboratories, learn more about integrating NGS into viral safety programs and how these methods support the path to faster, safer, and more ethical biologics manufacturing.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.